// App-Quantinova.ai

1026 : Biomarker panel (TheraPrint) analyzed as a predictor of response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.

Researchers

Presenter

  • Peter D. Beitsch

Principal Investigators

  • Lisette Stork

  • Femke De Snoo

  • Justine Peeters

  • Pat W. Whitworth

Medical Centers

  • Agendia, Amsterdam, Netherlands

  • Nashville Breast Center, Nashville, TNDallas Surgical Group, Dallas, TX

Locations

  • United States

  • Netherlands

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

  • Solid malignancies

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • Positive

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT014799101

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved